Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2022; 12(10): 31-48


A triterpenoid friedelan-3ß-ol isolated from Euphorbia lactea exhibited cytotoxic activity against HN22 cells by inducing an S-phase cell cycle arrest

Pawaris Wongprayoon, Sucharat Leelasart, Jintana Jantham, Yupa Pootaeng-on, Sittisak Oekchuae, Panupun Limpachayaporn, Kanok-on Rayanil, Purin Charoensuksai.




Abstract
Cited by 3 Articles

The anticancer activity of Euphorbia lactea Haw. (E. lactea) has been observed by our lab and other research groups; however, the identity of the bioactive compounds harboring the anticancer effect remains unknown. Here, we report the first isolation of four triterpenoidal compounds, i.e., friedelin [1], friedelan-3β-ol [2], taraxerol [3], and friedelan- 3α-ol [4], from the n-hexane fraction of the E. lactea extract. The cytotoxic activities of these compounds were investigated in several cancer cell lines, including HN22, HepG2, HCT116, and HeLa. These compounds exhibited a dose-dependent cytotoxic activity against HN22, HepG2, and HCT116, while the marginal cytotoxic effect was observed in HeLa cells. Among the four bioactive compounds, compound 2 exhibited the most prominent anticancer effect against HN22 cells. Flow cytometry analysis of HN22 cells treated with the compound revealed that compound 2 induced a cell cycle arrest at the S-phase, while apoptosis was not induced at the same concentration and exposure time. In summary, our results highlighted E. lactea as an attractive candidate for anticancer research and identified compound 2 as a chemical constituent of E. lactea harboring anticancer activity.

Key words: Euphorbia lactea, friedelan-3β-ol, cytotoxic, anticancer, triterpenoid






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.